Ethical Pharmaceutical Business
We have been providing with various pharmaceuticals for over 70 years as
the pharmaceutical business segment of Meiji Seika Kaisha, Ltd., our predecessor,
since beginning production of penicillin in 1946. We will continue supporting people’s
health and lives as a “Speciality & Generic Pharmaceutical Company.”
Our pharmaceutical business had a history of over 70 years since Meiji Seika Kaisha, Ltd., our predecessor began with its development of penicillin in 1946. Following commencing penicillin production, we started selling our STREPTOMYCIN Meiji for tuberculosis treatment in 1950. We launched Japan’s first internationally viable drug, KANAMYCIN Meiji, in 1958. As Japan’s top manufacturer of antibacterial drugs, we established our own manufacturing and development technologies, providing a series of excellent antibacterial drugs.
In 1990, we launched HABEKACIN, the first MRSA infection treatment in Japan. In 1994, we launched our MEIACT, an oral cephalosporin antibiotic In 2009, we launched ORAPENEM, the world’s only oral carbapenem antibacterial drug. Progress and wider use of antibiotics has saved people suffering from infections, greatly contributing to longevity and health promotion. In contrast, there has been an increase in CNS disorders, as well as cardiovascular and metabolic disorders, due to various causes, such as advent of the aging society in Japan, changing of living environments and stress. In response to these medical needs, in the CNS disorders field, we launched the antianxiety drug MEILAX in 1989; Japan’s first selective serotonin reuptake inhibitors (SSRI), DEPROMEL, in 1999; and Japan’s first noradrenergic and specific serotonergic antidepressant (NaSSA), REFLEX, in 2009. Further, we launched SYCREST for treatment of schizophrenia in 2016. Meiji Seika Pharma aims to become a leading company in the CNS disorders field.
Applying our know-how cultivated in the new drugs business, Meiji Seika Pharma leads other companies has been working to develop its generic pharmaceutical business as a “Speciality & Generic Pharmaceutical Company.” In the generic business, we have been quick to establish an organization which centralizes the functions of business planning, drug research, product development and sales, while simultaneously making more strenuous efforts on quality assurance, information provision and a stable supply. While we are strengthening our generic drug pipeline with a main focus on infectious diseases and CNS disorders, the mainstay fields in our speciality drug business, we are providing highly convenient and high-quality “useful generics,” as well to meet diverse medical needs.
Aiming to meet diversified medical needs, Meiji Seika Pharma is building new R&D technical basis and is working on approaches for targeting new fields. We will continue drug discovery research initiatives in the infectious diseases field while advancing research in such new fields as biopharmaceuticals and regenerative medicine. We are also eagerly working to develop treatments for unmet medical needs, and for cancer and other intractable diseases. To further expand and enhance our generic drug business, we are also investing strong efforts in biosimilars. In this way, Meiji Seika Pharma is working to evolve its “Speciality & Generic” model in its ethical pharmaceutical business.
Ethical Pharmaceutical Business